Details of the Drug Combination

General Information of Drug Combination (ID: DCCCS4I)

Drug Combination Name
Potassium Citrate Torasemide
Indication
Disease Entry Status REF
Congenital Mitral Insufficiency Phase 1 [1]
Component Drugs Potassium Citrate   DMRBUPA Torasemide   DMXKJ6C
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Potassium Citrate
Disease Entry ICD 11 Status REF
Hypokalemia 5C77 Approved [2]
Kidney stone GB70.0Z Approved [3]
Renal tubular acidosis N.A. Approved [2]
Indication(s) of Torasemide
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [4]
Edema MG29 Approved [5]
Renal hypoplasia N.A. Approved [6]
Torasemide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Solute carrier family 12 member 1 (SLC12A1) TTS087L S12A1_HUMAN Blocker [7]
------------------------------------------------------------------------------------
Torasemide Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Torasemide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Torasemide Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Increases Hydroxylation [11]
Solute carrier family 12 member 2 (SLC12A2) OT3ZJ3LH S12A2_HUMAN Decreases Activity [12]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Heart Failure Congenital DCEC9GY N. A. Phase 1 [13]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT06037434) Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation
2 Potassium Citrate FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7312).
5 Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials. Heart Fail Rev. 2021 Jan;26(1):127-136.
6 Torsemide. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
7 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
8 Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
9 Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics. 1997 Feb;7(1):51-8. doi: 10.1097/00008571-199702000-00007.
12 Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018 Jun 29;8(1):9877. doi: 10.1038/s41598-018-27995-w.
13 ClinicalTrials.gov (NCT06039540) Study of Drug Therapy for Pediatric Heart Failure